Burning Rock Biotech, a Guangzhou diagnostics company, closed a $126 million Series C financing led by GIC (the Sovereign Wealth Fund of Singapore). Burning Rock specializes in oncology diagnostics for precision medicine based on Next-Gen Sequencing. So far, the company has developed 32 products for different cancer types and clinical applications. It will use the proceeds of the funding to develop tests for early detection of cancer and to expand sales and marketing for its companion diagnostics business. Burning Rock also offers CRO services.
Source: ChinaBio Today (http://www.chinabiotoday.com/articles/Burning-Rock-125-Million)